Goldman Sachs Added Coventry Health Care (CVH) to its Conviction Sell List
More News related to CVH
- Credit Suisse Initiates Coverage on U.S. Managed Care and Several Sector Stocks
- GTCR Announces Partnership with Dale Wolf to Form Jessamine Healthcare
- Notable Analyst Rating Changes 08/02: KO, MJN, IBN, CVH Upgraded; ARNA, MU, LLTC, BPO Downgraded
- Leerink Swann Raises Coventry (CVH) to Outperform Following Q2 Earnings
- Coventry Health (CVH) Posts Q2 EPS of $1.01, Stronger than Views; Guides FY10 EPS and Revs
More News related to Analyst Comments
- FBR Capital on Hardline Retail: Housekeeping on TSCO, ODP & HGG
- Citi Weekly REIT and Lodging Strategy: Some Extra Income for the Long Weekend
- Barclays Maintains an 'Overweight' Rating on Lexmark Int'l (LXK); Valuation Still Attractive
- Barclays Reiterates an 'Overweight' Rating on Xerox (XRX); Valuation Still Attractive
- Barclays Reiterates an 'Overweight' Rating on The Hanover Insurance Group (THG) After Meeting W/Management
Goldman Sachs added Coventry Health Care, Inc. (NYSE: CVH) to its Conviction Sell List with downside 6-month price target of $20.
The firm said, "our view is based on sector-relative valuation with CVH trading at a 20% premium to the average forward PE of other core names (the last 5 years CVH has traded at a 16% discount on average)." They said the premium is unwarranted.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Create E-mail AlertRelated Categories
Analyst CommentsTrader Talk
Stocks Mentioned
+0.45Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
